178 related articles for article (PubMed ID: 21321401)
1. JNK3 as a therapeutic target for neurodegenerative diseases.
Antoniou X; Falconi M; Di Marino D; Borsello T
J Alzheimers Dis; 2011; 24(4):633-42. PubMed ID: 21321401
[TBL] [Abstract][Full Text] [Related]
2. Targeting JNK3 for the treatment of neurodegenerative disorders.
Resnick L; Fennell M
Drug Discov Today; 2004 Nov; 9(21):932-9. PubMed ID: 15501728
[TBL] [Abstract][Full Text] [Related]
3. K252a prevents nigral dopaminergic cell death induced by 6-hydroxydopamine through inhibition of both mixed-lineage kinase 3/c-Jun NH2-terminal kinase 3 (JNK3) and apoptosis-inducing kinase 1/JNK3 signaling pathways.
Pan J; Wang G; Yang HQ; Hong Z; Xiao Q; Ren RJ; Zhou HY; Bai L; Chen SD
Mol Pharmacol; 2007 Dec; 72(6):1607-18. PubMed ID: 17855652
[TBL] [Abstract][Full Text] [Related]
4. Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration.
Probst GD; Bowers S; Sealy JM; Truong AP; Hom RK; Galemmo RA; Konradi AW; Sham HL; Quincy DA; Pan H; Yao N; Lin M; Tóth G; Artis DR; Zmolek W; Wong K; Qin A; Lorentzen C; Nakamura DF; Quinn KP; Sauer JM; Powell K; Ruslim L; Wright S; Chereau D; Ren Z; Anderson JP; Bard F; Yednock TA; Griswold-Prenner I
Bioorg Med Chem Lett; 2011 Jan; 21(1):315-9. PubMed ID: 21112785
[TBL] [Abstract][Full Text] [Related]
5. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR studies of 1,2-diaryl-1H-benzimidazole derivatives as JNK3 inhibitors with protective effects in neuronal cells.
Kim MH; Ryu JS; Hah JM
Bioorg Med Chem Lett; 2013 Mar; 23(6):1639-42. PubMed ID: 23416008
[TBL] [Abstract][Full Text] [Related]
7. The neuroprotective effects of K252a through inhibiting MLK3/MKK7/JNK3 signaling pathway on ischemic brain injury in rat hippocampal CA1 region.
Pan J; Zhang QG; Zhang GY
Neuroscience; 2005; 131(1):147-59. PubMed ID: 15680699
[TBL] [Abstract][Full Text] [Related]
8. Deletion of the c-Jun N-terminal kinase 3 gene protects neonatal mice against cerebral hypoxic-ischaemic injury.
Pirianov G; Brywe KG; Mallard C; Edwards AD; Flavell RA; Hagberg H; Mehmet H
J Cereb Blood Flow Metab; 2007 May; 27(5):1022-32. PubMed ID: 17063149
[TBL] [Abstract][Full Text] [Related]
9. Use of cell-permeable peptides to prevent neuronal degeneration.
Borsello T; Bonny C
Trends Mol Med; 2004 May; 10(5):239-44. PubMed ID: 15121051
[TBL] [Abstract][Full Text] [Related]
10. Different protection of K252a and N-acetyl-L-cysteine against amyloid-beta peptide-induced cortical neuron apoptosis involving inhibition of MLK3-MKK7-JNK3 signal cascades.
Xu Y; Hou XY; Liu Y; Zong YY
J Neurosci Res; 2009 Mar; 87(4):918-27. PubMed ID: 18951497
[TBL] [Abstract][Full Text] [Related]
11. JNK signalling: a possible target to prevent neurodegeneration.
Borsello T; Forloni G
Curr Pharm Des; 2007; 13(18):1875-86. PubMed ID: 17584114
[TBL] [Abstract][Full Text] [Related]
12. Activated glia induce neuron death via MAP kinase signaling pathways involving JNK and p38.
Xie Z; Smith CJ; Van Eldik LJ
Glia; 2004 Jan; 45(2):170-9. PubMed ID: 14730710
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.
Cao J; Gao H; Bemis G; Salituro F; Ledeboer M; Harrington E; Wilke S; Taslimi P; Pazhanisamy S; Xie X; Jacobs M; Green J
Bioorg Med Chem Lett; 2009 May; 19(10):2891-5. PubMed ID: 19361991
[TBL] [Abstract][Full Text] [Related]
14. Activation of c-Jun NH2-terminal kinase 3 is mediated by the GluR6.PSD-95.MLK3 signaling module following cerebral ischemia in rat hippocampus.
Tian H; Zhang QG; Zhu GX; Pei DS; Guan QH; Zhang GY
Brain Res; 2005 Nov; 1061(1):57-66. PubMed ID: 16256962
[TBL] [Abstract][Full Text] [Related]
15. Hydrogen peroxide-induced neuronal apoptosis is associated with inhibition of protein phosphatase 2A and 5, leading to activation of MAPK pathway.
Chen L; Liu L; Yin J; Luo Y; Huang S
Int J Biochem Cell Biol; 2009 Jun; 41(6):1284-95. PubMed ID: 19038359
[TBL] [Abstract][Full Text] [Related]
16. Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives as Novel and Isoform-Selective c-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases.
Dou X; Huang H; Li Y; Jiang L; Wang Y; Jin H; Jiao N; Zhang L; Zhang L; Liu Z
J Med Chem; 2019 Jul; 62(14):6645-6664. PubMed ID: 31268308
[TBL] [Abstract][Full Text] [Related]
17. The beta-arrestin-2 scaffold protein promotes c-Jun N-terminal kinase-3 activation by binding to its nonconserved N terminus.
Guo C; Whitmarsh AJ
J Biol Chem; 2008 Jun; 283(23):15903-11. PubMed ID: 18408005
[TBL] [Abstract][Full Text] [Related]
18. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
Gehringer M; Muth F; Koch P; Laufer SA
Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
[TBL] [Abstract][Full Text] [Related]
19. The neuroprotective action of JNK3 inhibitors based on the 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold.
Graczyk PP; Khan A; Bhatia GS; Palmer V; Medland D; Numata H; Oinuma H; Catchick J; Dunne A; Ellis M; Smales C; Whitfield J; Neame SJ; Shah B; Wilton D; Morgan L; Patel T; Chung R; Desmond H; Staddon JM; Sato N; Inoue A
Bioorg Med Chem Lett; 2005 Nov; 15(21):4666-70. PubMed ID: 16153829
[TBL] [Abstract][Full Text] [Related]
20. Biological Properties of JNK3 and Its Function in Neurons, Astrocytes, Pancreatic β-Cells and Cardiovascular Cells.
Nakano R; Nakayama T; Sugiya H
Cells; 2020 Jul; 9(8):. PubMed ID: 32751228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
